INDP

INDP

Indaptus Therapeutics Inc

Rev โ€”top 1%10Y
Hold

Indaptus Therapeutics develops anti-cancer and anti-viral immunotherapies, with its lead candidate Decoy20 targeting lymphoma, solid tumors, and chronic hepatitis B and HIV infections, aiming for durable treatment responses in various cancers.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth9.55%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-144.54%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-41.13%
Net Trend30%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency
All Time
Scoreโ€”
Net Growth-162.75%
Net Trend27%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Indaptus Therapeutics Inc fundamental performance

Across Indaptus Therapeutics Inc's full reported history, from 2015 to 2025, net income went from -$ 7M to -$ 20M. Revenue increased in 0% of the years measured; net income in 27%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.02โ€”
1 Year2025-08-12
$ 8.24-87.62%
5 Years2021-08-12
$ 249.76-99.59%
10 Years2016-08-12
$ 13.19K-99.99%
All Time2015-08-04
$ 13.44K-99.99%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 18M$ 1M
2025$ 0.00-$ 20M$ 8M
2024$ 0.00-$ 15M$ 5M
2023$ 0.00-$ 15M$ 13M
2022$ 0.00-$ 14M$ 26M
2021$ 0.00-$ 7M$ 39M
2020$ 0.00-$ 3M$ 1M
2019-$ 47M$ 10M
2018-$ 43M$ 40M
2017-$ 28M$ 55M
2016-$ 13M$ 18M
IPO2015-$ 7M$ 30M

Explore beyond INDP

You're looking at Indaptus Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies